S. Cazzamalli

A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates

The paper develops a mass spectrometry-based method to quantify tumor-targeting small molecule-metal conjugates and validates it against radioactive biodistribution data.

A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake

This paper develops a dimeric FAP-targeting radioligand with prolonged tumour uptake and improved tumour-to-organ ratio, showing potent anti-tumour efficacy in preclinical models.

Antibody-based delivery of Interleukin-9 to neovascular structures: therapeutic evaluation in cancer and arthritis

This study evaluates the therapeutic potential of IL9 delivered via antibody-based fusion proteins in cancer and arthritis models, finding modest anti-tumor activity but no benefit in arthritis.

Sortase-mediated site-specific modification of interleukin-2 for the generation of a tumor targeting acetazolamide-cytokine conjugate

This paper develops a tumor-targeting cytokine conjugate using Sortase A-mediated site-specific modification of interleukin-2 with acetazolamide, targeting carbonic anhydrase IX.

Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX

This study shows that combining SMDCs targeting carbonic anhydrase IX with immunotherapy enhances anticancer activity in mouse models of renal cell carcinoma and colorectal cancer.

Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade

This study shows that transient RIPK1 inhibition increases the tolerated dose of L19-TNF while preserving its antitumor effects and tumor targeting.

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors

This paper describes a fusion protein that delivers interleukin-12 to tumors, enhancing NK and CD8+ T cell activity and synergizing with checkpoint inhibitors.